Pavia D, Lopez-Vidriero M T, Agnew J E, Taylor R G, Eyre-Brook A, Lawton W A, Pellow P G, Clarke S W
Department of Thoracic Medicine, Royal Free Hospital and Bracknell, Berkshire, UK.
Respiration. 1989;55(1):33-43. doi: 10.1159/000195703.
The effect of oxitropium bromide on lung mucociliary clearance, pulmonary function and viscoelastic properties of sputum was investigated in 10 asthmatics and 10 chronic bronchitics. A controlled, double-blind, crossover study was performed. Following a baseline (B) measurement the patients were, in a random order, allocated placebo (P) or oxitropium bromide (O; 0.1 mg/puff), administered from metered dose inhalers, which they used for 4 weeks at a dose of 2 puffs t.d.s. This test medication was used in conjunction with their normal medication. At the end of the treatment period the patients were assessed, the treatments were then crossed over and a final assessment made 4 weeks later. The administration of oxitropium bromide resulted in (1) small but statistically significant increases in pulmonary function (less than 10% vs. placebo); (2) increased penetrance of radioaerosol into the lungs (mean +/- SEM alveolar deposition: 35 +/- 3, 26 +/- 3 and 24 +/- 3% for the O, P and B runs respectively; p less than 0.025); (3) no significant change in particle clearance rate from the lungs despite their deeper penetration (mean +/- SEM area under the tracheobronchial clearance curves between 0 and 6 h: 317 +/- 26, 324 +/- 25 and 287 +/- 25%.h for the O, P and B runs respectively; p greater than 0.1); (4) no alteration in sputum production, and (5) no significant changes in apparent viscosity (mean +/- SEM: 640 +/- 162, 446 +/- 79 and 557 +/- 115 mPa.s for the O, P and B runs, respectively; p greater than 0.1) and elasticity (mean +/- SEM: 3,682 +/- 1,383, 1,779 +/- 353 and 2,061 +/- 366 mPa for the O, P and B runs, respectively; p greater than 0.1) of sputum. When the two groups, i.e. the chronic bronchitics and asthmatics, were studied separately, no significant differences in any parameter measured (other than radioaerosol penetrance which was significantly enhanced on oxitropium bromide in chronic bronchitics) were noted between the three assessments.
在10名哮喘患者和10名慢性支气管炎患者中研究了氧托溴铵对肺黏液纤毛清除功能、肺功能及痰液黏弹性的影响。进行了一项对照、双盲、交叉研究。在进行基线(B)测量后,患者被随机分配接受安慰剂(P)或氧托溴铵(O;0.1mg/喷),通过定量吸入器给药,他们以每日3次、每次2喷的剂量使用4周。该试验药物与他们的常规药物联合使用。在治疗期结束时对患者进行评估,然后进行治疗交叉,并在4周后进行最终评估。氧托溴铵的给药导致:(1)肺功能有小幅度但具有统计学意义的增加(与安慰剂相比增加不到10%);(2)放射性气雾剂在肺内的穿透增加(平均±标准误肺泡沉积率:O组、P组和B组分别为35±3%、26±3%和24±3%;p<0.025);(3)尽管气雾剂在肺内的穿透更深,但肺内颗粒清除率无显著变化(0至6小时气管支气管清除曲线下面积的平均±标准误:O组、P组和B组分别为317±26%·h、324±25%·h和287±25%·h;p>0.1);(4)痰液分泌无改变;(5)痰液的表观黏度(平均±标准误:O组、P组和B组分别为640±162mPa·s、446±79mPa·s和557±115mPa·s;p>0.1)和弹性(平均±标准误:O组、P组和B组分别为3682±1383mPa、1779±353mPa和2061±366mPa;p>0.1)无显著变化。当分别对慢性支气管炎患者和哮喘患者这两组进行研究时,在三次评估之间,所测量的任何参数(除慢性支气管炎患者中氧托溴铵使放射性气雾剂穿透显著增强外)均未发现显著差异。